# Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors

> **NCT07123493** · EARLY_PHASE1 · TERMINATED · sponsor: **Haifeng Qin** · enrollment: 1 (actual)

## Conditions studied

- Recurrent or Metastatic Solid Tumors With Positive ALPP

## Interventions

- **BIOLOGICAL:** Anti ALPP CAR-T cells treatment

## Key facts

- **NCT ID:** NCT07123493
- **Lead sponsor:** Haifeng Qin
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-08-28
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Strategic Portfolio Decision
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07123493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07123493, "Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07123493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*